CRON Cronos Group Inc. Quarterly EPS earnings growth

thecronosgroup.com - graphic logo of issuer CRON

Cronos Group Inc. (CRON) expects major M&A deals due to stagnant organic growth. This quarterly EPS trend captures the asset's market position, where -44.70 records the current value of the indicator. Financial stability is ensured by Altria's support and an asset-light model. High customer confidence is based on strict quality control and an innovative approach to developing medical products.

Cronos Group (CRON) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Cronos Corp (CRON)

- market value and analyst target forecast:
Price Chart Cronos Group|CRON - Consensus Target
- market capitalization data:
Market Capitalization Cronos|CRON - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Cronos Group|CRON - Accounting Value of Company|Market Value to Book Value Ratio thecronosgroup.com|CRON - Company Assets
- debt and liquidity details:
Debt to Equity Cronos Group Inc.|CRON - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Cronos Group Inc.|CRON - Company Cumulative Debt|Debt to Book Capitalization Ratio Cronos|CRON - Long-Term Debt Volume|Company Current Liabilities Cronos Group|Quick Ratio thecronosgroup.com
- earnings and market multiples details:
CRON - Annual Net Income|Expected Profit Cronos Group Inc.|CRON - Company Value to Net Income|Future Price to Earnings Cronos|CRON - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Cronos|CRON - Operating profit EBITDA|Earnings per share for the last twelve months Cronos Group|CRON - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months thecronosgroup.com|CRON - Earnings per share increase in current year|Earnings growth forecast for next year Cronos Group Inc.
- sales revenue and business income indicators:
CRON - Company Gross Revenue|Company Projected Revenue Cronos Group|CRON - Market Cap to Revenue Ratio|Forward P/S Multiple Cronos
Comprehensive company analysis:Cronos Group Inc.
Manufactured product of Cronos Group Inc.

Quarterly earnings per share (EPS) growth serves as a key filter to separate market noise from actual business efficiency. This metric measures the percentage change in net income attributable to each common share compared to the same period last year. By analyzing quarterly EPS growth rates, an investor assesses the dynamics of cash generation. For Cronos Group Inc. (CRON), such indicators confirm the effectiveness of Mike Gorenstein's conservative cost management. A massive liquidity reserve and majority shareholder support make this growth fundamentally sustainable.

Competitors of Cronos Group Inc. (CRON)

Indivior (INDV) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Collegium Pharma|CGC (Tweed) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Canna Cabana (HITI)|Year-over-year earnings per share growth for the last twelve months Aurora Cannabis (ACB)|ACHV (achievelifesciences.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Skye Bioscience, Inc. SKYE|Anebulo Pharmaceuticals Inc (ANEB) - Earnings per share growth in annualized terms for the last twelve months|INCR - Year-over-year earnings per share growth for the last twelve months|NTRB (Nutriband Inc.) - Year-over-year earnings per share growth for the last 12 months|nasuspharma.com (NSRX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months IGC Pharma (IGC)|Year-over-year earnings per share growth for the last twelve months MIRA Pharmaceuticals Inc.|Flora Growth Corp (FLGC) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months IMCC (IM Cannabis Corp.)|ADIL (adialpharma.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTL (Artelo Biosciences, Inc.)|Net earnings per share growth for the trailing year Ensysce Biosciences Inc.|TTNP - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months GNLN (Greenlane Holdings, Inc.)|InMed Pharma (INM) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Akanda Inc (AKAN)|Year-over-year net earnings per share growth for the last 12 months ENVB|Quarterly EPS earnings growth Bright Green Corp|Year-over-year earnings per share growth for the last twelve months Hempacco (HPCO)